Long-Term Oncological Outcomes in Intermediate-Risk Cervical Cancer After Radical Surgery: A Single-Center Retrospective Cohort Study

Background/Objectives: The optimal postoperative management of intermediate-risk cervical cancer remains uncertain. We aimed to describe long-term outcomes and explore differences by postoperative treatment. Methods: This single-center retrospective cohort study included patients undergoing radical hysterectomy and pelvic lymph node assessment who fulfilled intermediate-risk criteria aligned with the CERVANTES trial. Disease-free survival (DFS) was the primary outcome and overall survival (OS) the secondary outcome. Observed 3- and 5-year survival proportions were compared among patients with documented follow-up at each time point. Results: Of 186 patients undergoing primary surgery, 41 fulfilled the intermediate-risk criteria: 30 were managed with surgery alone and 11 received adjuvant treatment. Median maximum tumor diameter was smaller in the surgery-alone group than in the adjuvant-treatment group (28.5 mm [IQR, 24.25–34.00] vs. 41.0 mm [IQR, 33.5–47.5]; p = 0.003), and FIGO stage IB3 was less frequent (6.7% vs. 63.6%; p < 0.001). No recurrences or deaths occurred in the surgery-alone group. One patient in the adjuvant-treatment group died from an unrelated cause; this was the only DFS event. At 3 years, observed OS and DFS were 100% (23/23) in the surgery-alone group and 90.0% (9/10) in the adjuvant-treatment group (p = 0.303). At 5 years, the corresponding proportions were 100% (16/16) and 85.7% (6/7; p = 0.304). Conclusions: Patients managed with surgery alone had favorable observed outcomes. However, baseline risk differed between groups, and time-point proportions included only patients with documented follow-up. The retrospective design, small sample, and non-randomized allocation preclude conclusions about the comparative effectiveness or safety of omitting adjuvant treatment. Prospective randomized studies are needed.

Authors

Institutions

Publication Details

Journal
Cancers
Published
2026-11-12
DOI
https://doi.org/10.3390/cancers18223612
Primary Topic
Endometrial and Cervical Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Long-Term Oncological Outcomes in Intermediate-Risk Cervical Cancer After Radical Surgery: A Single-Center Retrospective Cohort Study

Szilárd Leó Kiss, Márton Keszthelyi, Richárd Tóth, Dan Mihai Căpîlna et al.
Cancers
Endometrial and Cervical Cancer Treatments
article

Long-Term Oncological Outcomes in Intermediate-Risk Cervical Cancer After Radical Surgery: A Single-Center Retrospective Cohort Study

Szilárd Leó Kiss, Márton Keszthelyi, Richárd Tóth, Dan Mihai Căpîlna, Balázs Lintner, Francis P Banhidy, Balázs Vida, Ádám Tabányi, Pál Sebok, Csongor Kárpáti, Ákos Molnár-Csendom, Lőczi Lotti
article en

Abstract

Background/Objectives: The optimal postoperative management of intermediate-risk cervical cancer remains uncertain. We aimed to describe long-term outcomes and explore differences by postoperative treatment. Methods: This single-center retrospective cohort study included patients undergoing radical hysterectomy and pelvic lymph node assessment who fulfilled intermediate-risk criteria aligned with the CERVANTES trial. Disease-free survival (DFS) was the primary outcome and overall survival (OS) the secondary outcome. Observed 3- and 5-year survival proportions were compared among patients with documented follow-up at each time point. Results: Of 186 patients undergoing primary surgery, 41 fulfilled the intermediate-risk criteria: 30 were managed with surgery alone and 11 received adjuvant treatment. Median maximum tumor diameter was smaller in the surgery-alone group than in the adjuvant-treatment group (28.5 mm [IQR, 24.25–34.00] vs. 41.0 mm [IQR, 33.5–47.5]; p = 0.003), and FIGO stage IB3 was less frequent (6.7% vs. 63.6%; p < 0.001). No recurrences or deaths occurred in the surgery-alone group. One patient in the adjuvant-treatment group died from an unrelated cause; this was the only DFS event. At 3 years, observed OS and DFS were 100% (23/23) in the surgery-alone group and 90.0% (9/10) in the adjuvant-treatment group (p = 0.303). At 5 years, the corresponding proportions were 100% (16/16) and 85.7% (6/7; p = 0.304). Conclusions: Patients managed with surgery alone had favorable observed outcomes. However, baseline risk differed between groups, and time-point proportions included only patients with documented follow-up. The retrospective design, small sample, and non-randomized allocation preclude conclusions about the comparative effectiveness or safety of omitting adjuvant treatment. Prospective randomized studies are needed.

CancersVol. 18(22)
Semmelweis University (HU), Barts Health NHS Trust (GB), Royal London Hospital (GB), Universitatea de Medicină, Farmacie, Științe și Tehnologie „George Emil Palade” din Târgu Mureș (RO)
Good health and well-being
Endometrial and Cervical Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon